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Purpose of the study
To assess the impact of lamivudine (3TC) monotherapy in failing patients with multidrug-resistant HIV and limited therapeutic
options.
Methods
Prospective, open-label, multicenter, randomised (1:1), pilot study. HIV-1 failing pts with M184V mutation, HBsAg negative were
assigned to 3TC 300mg QD for 24 weeks followed by a new regimen for 24 weeks (Arm A) or to a new regimen for 48 weeks
(Arm B).The new HAARTregimen was decided before randomisation in both groups, based on clinical history, genotype and viral
tropism. Primary endpoint was the proportion of pts with HIV-RNAB50 copies/mL (VS) at week 48 (W48). ITT and OT analysis
performed. Results described by median (IQR).
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Table 1. Virological success according to Nadir CD4, screening HIVRNA and GSS of the new regimen.
ITT ANALYSIS
Characteristic Strata
Percent of patients with
HIV-RNA B50 copies/mL at
week 48 in Arm A
Percent of patients with
HIV-RNA B50 copies/mL at
week 48 in Arm B P-value
Breslow-Day
Test P-value
Nadir Cd4(cells/mL) B200 10/24 42% 10/24 42% 0.999 0.173
]200 5/14 (36%) 7/10 (70%) 0.214
Screening HIV-RNA 5110000 15/26 (58%) 15/26 (58%) 0.999 0.092
(copies/mL)  10000 0/12 2/8 (25%) 0.147
New Regimen GSS B2 3/7 (43%) 3/8 (38%) 0.999 0.479
]2 12/31 (39%) 14/26 (54%) 0.294
OT Analysis
Characteristic Strata
Percent of patients with
HIV-RNA B50 copies/mL at
week 48 in Arm A
Percent of patients with
HIV-RNA B50 copies/mL at
week 48 in Arm B P-value
Breslow-Day
Test P-value
Nadir Cd4(cells/mL) B200 10/12 (83%) 10/19 (53%) 0.128 0.027
]200 5/9 (56%) 7/8 (88%) 0.294
Screening HIV-RNA 5110000 15/17 (88%) 15/22 (68%) 0.251 0.052
(copies/mL)  10000 0/4 (0%) 2/5 (40%) 0.444
New Regimen GSS B2 3/4 (75%) 3/5 (60%) 0.999 0.816
]2 12/17 (71%) 14/22 (64%) 0.740
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1Summary of results
109 screened, 34 screening failures, 75 randomised, 72 initiated the assigned treatment [38 and 34 pts in Arm A and B,
respectively]: 69% males; age: 47.4 (43.251.9) years; years of HIV infection: 17 (1423); nadir CD4: 150 (47231) cells/mL.
Similar baseline demographic and clinical characteristics were found in Arm A vs Arm B [CD4: 413 (294550) vs 377 227520)
cells/mL; HIV-RNA: 3.94 (2.894.43) vs 3.66 (2.784.20) log10copies/mL; number of mutations: 9 (513) vs 9 (319); R5-virus:
67% vs 50%; new regimen GSS: 2 (23) vs 2 (22); 60% vs 56% pts included in the new regimen at least two of the following
drugs: DRV/r, MVC, RAL, ETR, T-20]. At W48, pts with VS were 15/38 (39%) vs 17/34 (50%) in Arm A and B, respectively
(ITT: P0.477). In Arm A, 25/38 (66%) completed the 24-weeks of monotherapy and 21 reached week 48 vs 27 pts in Arm B
(P0.045). Pts with VS were 15/21 (71%) vs 17/27 (63%) in Arm A and B, respectively (OT: P0.758). VS according to nadir
CD4, screening HIVRNA and GSS of the new regimen shown in Table 1. SAEs occurred in 4 (11%) and 2 (6%) in Arm A and B,
respectively; all but 1 in Arm A unrelated to the regimen; 4 CDC events: 3 oral candidiasis and 1 recurrence of CMV infection in
Arm A; 1 oral candidiasis in Arm B. W48 CD4 change from baseline was: ITT:4( 108/56) and 53 (37/110) cells/L
(P0.735); OT: 8 (62/58) and 68 (24/148) cells/L in arm A and B, respectively (P0.500). Mutations associated with
resistance at W48 were 4 (07) and 7 (213) in Arm A and B, respectively (P0.031). R5 virus at W48: Arm A55% vs Arm
B29% (P0.124).
Conclusions
Use of 3TC monotherapy was associated with greater discontinuation. It may be considered in patients without effective
therapeutic options to favour virological efficacy of the subsequent regimen.
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